PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28118381-2	2017	The rapid virological response rates in patients receiving TVR-based triple therapy were 92% (23/25) and 40% (10/25) for CAP/CTM and ART, respectively.	telaprevir	59-62	heat shock transcription factor 4	Homo sapiens	121-136	
28118381-4	2017	In an independent examination of 20 patients receiving TVR-based triple therapy who developed viral breakthrough or relapse, the times to HCV disappearance by ART were longer than by CAP/CTM, whereas the times to HCV reappearance were similar.	telaprevir	55-58	heat shock transcription factor 4	Homo sapiens	187-190